A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer
Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This research study is being performed at approximately 3 sites associated with Accelerated
Community Oncology Research Network, Inc. (ACORN). Approximately 45 subjects will take part
in this study.
In this study, everyone will receive the same dose of mFOLFOX6 and Avastin. There will be
five groups of subjects. Each group of subjects will receive a higher dose of Nexavar than
the previous group. This will continue until a subject group has a major side effects from
the dose they are given. This is so that the sponsor can determine the highest dose of
Nexavar that can be used with mFOLFOX6 and AVastin (this is called the maximum tolerated dose
or MTD).